Literature DB >> 12220297

Cholestatic liver disease: pathophysiology and therapeutic options.

Alan F Hofmann1.   

Abstract

Cholestasis results from defective canalicular secretion of bile or obstruction to bile flow distal to the canaliculus. In early primary biliary cirrhosis, bile secretion continues, because of the secretory pressure of bile or because some ductules are not obstructed. With complete cholestasis, a bile acid deficiency occurs in the small intestinal lumen leading to lipid maldigestion and fat-soluble vitamin malabsorption. Bacterial proliferation, bacterial translocation to lymph nodes and endotoxemia may also occur leading to an acute phase reaction. Retention of bile acids in the hepatocyte leads to apoptosis. Accumulation of bile acids in the systemic circulation leads to pruritus, and may contribute to endothelial injury in the lungs and kidney. Early attempts to mimic hepatic excretory function by hemoperfusion over adsorbent columns were unsuccessful for a variety of reasons. Extracorporeal dialysis against albumin offers promise of a realistic albeit partial simulation of hepatic excretory function.

Entities:  

Mesh:

Year:  2002        PMID: 12220297     DOI: 10.1034/j.1600-0676.2002.00002.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  22 in total

1.  Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.

Authors:  C Rust; K Bauchmuller; C Bernt; T Vennegeerts; P Fickert; A Fuchsbichler; U Beuers
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

Review 2.  FXR and PXR: potential therapeutic targets in cholestasis.

Authors:  Johan W Jonker; Christopher Liddle; Michael Downes
Journal:  J Steroid Biochem Mol Biol       Date:  2011-07-20       Impact factor: 4.292

3.  Prognostic roles of tetrahydroxy bile acids in infantile intrahepatic cholestasis.

Authors:  Chee-Seng Lee; Akihiko Kimura; Jia-Feng Wu; Yen-Hsuan Ni; Hong-Yuan Hsu; Mei-Hwei Chang; Hiroshi Nittono; Huey-Ling Chen
Journal:  J Lipid Res       Date:  2017-01-10       Impact factor: 5.922

4.  Hepatic bile acid metabolism and expression of cytochrome P450 and related enzymes are altered in Bsep (-/-) mice.

Authors:  Eugene Hrycay; Dana Forrest; Lin Liu; Renxue Wang; Jenny Tai; Anand Deo; Victor Ling; Stelvio Bandiera
Journal:  Mol Cell Biochem       Date:  2014-01-08       Impact factor: 3.396

5.  Molecular Adsorbents Recirculating System dialysis in children with cholestatic pruritus.

Authors:  Betti Schaefer; Franz Schaefer; Dieter Wittmer; Guido Engelmann; Daniel Wenning; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2011-11-15       Impact factor: 3.714

Review 6.  The bile salt export pump: molecular properties, function and regulation.

Authors:  Marco Arrese; Meenakshisundaram Ananthanarayanan
Journal:  Pflugers Arch       Date:  2004-07-24       Impact factor: 3.657

7.  ANIT-induced intrahepatic cholestasis alters hepatobiliary transporter expression via Nrf2-dependent and independent signaling.

Authors:  Yuji Tanaka; Lauren M Aleksunes; Yue Julia Cui; Curtis D Klaassen
Journal:  Toxicol Sci       Date:  2009-01-29       Impact factor: 4.849

Review 8.  Aquaporins: their role in cholestatic liver disease.

Authors:  Guillermo-L Lehmann; Maria-C Larocca; Leandro-R Soria; Raul-A Marinelli
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

9.  Histopathology findings in common marmosets (Callithrix jacchus Linnaeus, 1758) with chronic weight loss associated with bile tract obstruction by infestation with Platynosomum (Loos, 1907).

Authors:  Maria Bernardete Cordeiro Sousa; Adriano Castro Leão; José Flávio Vidal Coutinho; Ana Maria de Oliveira Ramos
Journal:  Primates       Date:  2008-10-08       Impact factor: 2.163

10.  P-selectin glycoprotein ligand-1-mediated leukocyte recruitment regulates hepatocellular damage in acute obstructive cholestasis in mice.

Authors:  Stefan Dold; Matthias W Laschke; Yilin Zhau; Martin Schilling; Michael D Menger; Bengt Jeppsson; Henrik Thorlacius
Journal:  Inflamm Res       Date:  2009-10-15       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.